Co-Diagnostics, Inc. (CODX) Stock

Co-Diagnostics, Inc. (CODX) is a Healthcare stock trading at $3.29 (as of 2026-06-18), with a market capitalization of $2.75M and a trailing P/E of -0.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Co-Diagnostics, Inc. develops, manufactures, and sells molecular diagnostics reagents and tests that detect or analyze nucleic acid molecules. Its offerings include PCR-based diagnostic tests and platforms, multiplex assays for mosquito-borne disease identification, and additional molecular tools for infectious disease detection, liquid biopsy, and genetic trait testing in plant and animal genomes, plus a portable device intended to enable PCR testing at point of care and at home.

Valuation — source: SEC EDGAR (first-party)
Price	$3.29
Market Cap	$2.75M
P/E Ratio	-0.1
EV / EBITDA	-0.1
Price / Book	0.96
Price / Sales	21.52
DCF Value (model)	$-137.70
DCF Upside vs Price	-4285.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$622489.00
Net Margin	-7533.6%
Return on Equity	-302.3%
Current Ratio	2.28
Revenue Growth (YoY)	-84.1%
EPS Growth (YoY)	2742.7%
FCF Growth (YoY)	-0.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	-8.99 (distress)

Valuation vs Sector & Industry
Stock P/E	-0.1
Sector P/E (Healthcare)	20.9
Industry P/E (Medical Equipment)	31.7
vs Sector	-100.5%
vs Industry	-100.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($322641.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Dwight H. Egan
Employees	132
Country	US
IPO Date	2017-07-12

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.